Abbott agreed to acquire Exact Sciences in a cash deal valuing the diagnostics company at roughly $21–23 billion, moving Abbott decisively into cancer screening and precision oncology. Exact’s portfolio includes Cologuard colorectal screening, Oncotype DX breast recurrence assays, and liquid biopsy MRD and multi‑cancer early detection tests. Abbott said the acquisition will be immediately accretive to revenues and gross margin and will expand its diagnostics footprint globally.